A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2002
11/28/2002	US20020177192 Chimeric protein for use in the treatment of vision defects
11/28/2002	US20020177190 Nucleotide sequences coding polypeptide for use in the treatment of hypertension and vision defects
11/28/2002	US20020177173 Glycoprotein for use in the treatment of thrombosis
11/28/2002	US20020177166 Binding motif of a receptor
11/28/2002	US20020177165 Secreted and transmembrane polypeptides and nucleic acids encoding
11/28/2002	US20020177164 Secreted and transmembrane polypeptides and nucleic acids encoding the same
11/28/2002	US20020177150 Nucleoside composition for use as tool in human therapeutics and diagnositcs
11/28/2002	US20020177145 Detection and classification of nervous system progenitor cells; obtain tissue, monitor expression of daedalos protein in sample, compare to control, ampified daedalos expression indicates presence of nervous system progenitor cells
11/28/2002	US20020177128 Variant of LAV viruses
11/28/2002	US20020177125 Polypeptide for use in the treatment of viral disease
11/28/2002	US20020176911 Includes xanthan gum which improves tolerance (e.g. less gastrointestinal symptoms such as emesis, stool patterns and gas)
11/28/2002	US20020176904 Antiprotozal composition
11/28/2002	US20020176900 Source of calcium, magnesium, selenium, manganese, zinc, and potassium, vitamin E, vitamin A, alpha-lipoic acid, extracts of Allium sativum, Medicago sativa, and Chondrus crispus, L-cysteine, L-glutamic acid, glycine, and glutathione
11/28/2002	US20020176893 Applying a mixture of a water insoluble particle and a carrier; promotes inflammatory response; for closing of the vas deferens, lessening menstrual flow, repairing intervertebral disc rupture
11/28/2002	US20020176887 Methods of delivery of cetyl myristoleate
11/28/2002	US20020176872 Pain treatment by peripheral administration of a neurotoxin
11/28/2002	US20020176867 Fusion proteins of the immunodominant antigens ESAT-6 and Ag85B from Mycobacterium tuberculosis or homologues, and the vaccine based on fusion protein, which induces efficient immunological memory
11/28/2002	US20020176866 The peptide analog is at least seven amino acids long and derived from residues 83 to 99 of human myelin basic protein and analogs are altered from native sequence atleast at positin 91, 95 and 97
11/28/2002	US20020176864 Two-domain MHC polypeptides include MHC( major histocompatibility complex) class II-based molecules that covalently linked beta 1 and alpha 1 domains, and MHC class I-based molecules that covalently linked alpha-1 and alpha-2
11/28/2002	US20020176862 A protein (Sm 16.8) with anti-inflammatory, and immunomodulatory functions was identified and isolated from the excretory/secretions of a human parasite, Schistosoma manson
11/28/2002	US20020176859 Therapy of ototoxin- induced hearing impairments by administration of neurotrophins
11/28/2002	US20020176858 Monoclonal antibodies to TGF-BETA
11/28/2002	US20020176857 Culturing stromal cells with bone marrow, quantitative determining the concentration of interleukins by comparing to a standard curve; identifying a patient with a multiple myeloma- related plasmaproliferative disorder
11/28/2002	US20020176856 Administering an antibody to the mammal, that binds with a specified target epitope of an antigen, associated with a tumor or an infectious agent; having engineered glycosylation site in the constant region of the heavy chain antibodies
11/28/2002	US20020176852 Mitogenic oxygenase regulators
11/28/2002	US20020176851 Aministering to mammal an effective amount of therapeutic cells, expressing a membrane-bound, proteinaceous chimeric receptor, capable recognizing and binding target cell or infective agent; antitumor therapy
11/28/2002	US20020176850 Immunotherapy of cancer with allogeneic lymphocytes
11/28/2002	US20020176849 Endomural therapy
11/28/2002	US20020176847 Administering to a mammal viral vectors for treating and preventing atherosclerosis, osteoporosis, cardiovascular disease, Alzheimer's disease, diabetes mellitus, infectious diseases, cancer, and inherited disorders
11/28/2002	US20020176846 Storage stable powder compositions of interleukin-4 receptor
11/28/2002	US20020176841 Pharmaceutical formulations for sustained release
11/28/2002	US20020176819 Gastrin receptor-avid peptide conjugates
11/28/2002	DE10125033A1 Use of Sjoegren syndrome antigens as apoptotic targets, useful for diagnosis, treatment, e.g. of cancer or neurodegeneration, and drug screening
11/28/2002	DE10123958A1 Identifying ligands for G protein-coupled receptors, useful for treating cardiovascular disease, by using calcium-sensitive fluorophores in cells expressing G alpha proteins
11/28/2002	DE10123668A1 Induction or stimulation of intestinal calcium absorption, especially for combating vitamin D deficiency in babies or infants, by oral or parenteral administration of parathyroid hormone-related peptide or its fragment
11/28/2002	DE10122206A1 Novel use of 2',5'-oligoadenylate synthetase or RNAseL polypeptides, nucleic acids encoding polypeptides, cell expressing peptides and nucleic acids or antibody for analyzing, diagnosing, or treating wound healing
11/28/2002	DE10122140A1 Rekombinante Fusionsproteine und deren Trimere Recombinant fusion proteins and their trimers
11/28/2002	CA2464343A1 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
11/28/2002	CA2448668A1 Modulation of cd200 receptors
11/28/2002	CA2448364A1 Composition and methods for affecting metallocorrinoid uptake
11/28/2002	CA2448253A1 Human cdnas and proteins and uses thereof
11/28/2002	CA2448174A1 Compounds capable of modulating the activity and stimulating the production of a catalytic antibody
11/28/2002	CA2448142A1 Beta-secretase substrates and uses thereof
11/28/2002	CA2448132A1 Vectors for enhanced expression of vegf for disease treatment
11/28/2002	CA2448120A1 Muscle-specific expression vectors
11/28/2002	CA2448102A1 Novel mixed lineage kinase (7) (mlk7) polypeptide, polynucleotides encoding the same, and methods of use thereof
11/28/2002	CA2448092A1 Internalisation of virus into cells
11/28/2002	CA2448022A1 Compositions for protein delivery via the pulmonary route
11/28/2002	CA2448018A1 Compositions and methods for inhibiting metastasis
11/28/2002	CA2448014A1 Tsg101 as inhibitor of hiv production
11/28/2002	CA2447958A1 Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions
11/28/2002	CA2447795A1 Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof
11/28/2002	CA2447647A1 Lipid-associated molecules
11/28/2002	CA2447340A1 Kinases and phosphatases
11/28/2002	CA2447236A1 Pulmonary administration of chemically modified insulin
11/28/2002	CA2447023A1 Conjugates activated by cell surface proteases and therapeutic uses thereof
11/28/2002	CA2446510A1 Therapeutic agent for tumor of neural origin
11/28/2002	CA2446398A1 Nucleic acid and protein sequences of bovine epidermal growth factor
11/28/2002	CA2446049A1 The use of a gatran for the manufacture of a medicament for the treatment of pulmonary fibrosis
11/28/2002	CA2444955A1 Inactivation of genes of the mep pathway
11/28/2002	CA2443342A1 Mage-a3 peptides presented by hla class ii molecules
11/28/2002	CA2441840A1 Human secreted proteins
11/28/2002	CA2441666A1 Phytases, nucleic acids encoding them and methods and using them
11/28/2002	CA2440368A1 Staphylococcus aureus proteins and nucleic acids
11/28/2002	CA2440147A1 Nucleic acid and corresponding protein entitled 121p1f1 useful in treatment and detection of cancer
11/28/2002	CA2438597A1 Champ - a cardiac helicase-like factor
11/28/2002	CA2427381A1 Transdermal drug delivery devices having coated microprotrusions
11/27/2002	EP1260587A2 Tyrosyl tRNA synthetase
11/27/2002	EP1260586A2 Method and reagent for inhibiting the expression of disease related genes
11/27/2002	EP1260585A1 Novel protein and gene encoding the same
11/27/2002	EP1260582A1 Conjugates of factor IX and a biocompatible polymer
11/27/2002	EP1260521A2 Immunoglobulin variants for specific Fc epsilon receptors
11/27/2002	EP1260519A1 Membrane receptors for steroids and sterols
11/27/2002	EP1260231A1 Drugs for ameliorating retinal function
11/27/2002	EP1260230A1 Preparations stabilized over long time
11/27/2002	EP1260229A2 Anti-autoimmune composition comprising inhibitors of growth hormone-releasing factor activity
11/27/2002	EP1260228A2 Human growth gene and short stature gene region. Therapeutic uses
11/27/2002	EP1259818A2 Diagnosis and treatment of schizophrenia
11/27/2002	EP1259813A2 Diagnosis and treatment of malignant neoplasms
11/27/2002	EP1259812A2 Breast, gastric and prostate cancer associated antigens and uses therefor
11/27/2002	EP1259648A2 Diagnostics and therapeutics for glaucoma
11/27/2002	EP1259647A2 Methods for diagnosing, monitoring, staging, imaging and treating lung cancer via lung cancer specific genes
11/27/2002	EP1259642A1 Nucleic acids, proteins, and antibodies
11/27/2002	EP1259639A2 Essential gene and gene products for identifying, developing and optimising immunological and pharmacological active ingredients for the treatment of microbial infections
11/27/2002	EP1259638A2 Methods for selectively modulating survivin apoptosis pathways
11/27/2002	EP1259637A2 Caspase-inhibitory-factor (cif) and uses thereof
11/27/2002	EP1259627A2 Heterologous expression of neisserial proteins
11/27/2002	EP1259626A2 Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins and screening methods for modulators
11/27/2002	EP1259621A2 Lipid metabolism enzymes
11/27/2002	EP1259620A2 2504, 15977, and 14760, novel protein kinase family members and uses therefor
11/27/2002	EP1259618A2 Human enzyme molecules
11/27/2002	EP1259617A2 Bunyaviridal reaper proteins and uses therefor
11/27/2002	EP1259616A2 Tnf-alpha variants for the treatment of tnf-alpha related disorders
11/27/2002	EP1259614A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same
11/27/2002	EP1259612A2 G-protein coupled receptor related polypeptides
11/27/2002	EP1259611A2 G-protein coupled receptors
11/27/2002	EP1259609A2 Human schizophrenia gene
11/27/2002	EP1259607A2 Protein and gene and their use for diagnosis and treatment of schizophrenia
11/27/2002	EP1259606A2 Compositions useful for regulating parkin gene activity
11/27/2002	EP1259605A2 Mutated cyclin g1 protein

1 ... 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 ... 3163